

An Orally Administered Lavandula Oil Preparation (Silexan) for Anxiety Disorder and Related Conditions: An Evidence Based Review

Siegfried Kasper ¹

Affiliations

- PMID: [23808618](#)
- DOI: [10.3109/13651501.2013.813555](#)

Abstract

Objective: Silexan is a lavender oil preparation in gelatine capsules containing 80 mg. We reviewed the clinical trials investigating the anxiolytic efficacy and tolerability of Silexan as well as its safety and potential for drug interactions.

Methods: Seven trials were included, among which four therapeutic trials had a treatment duration of 6 or 10 weeks.

Results: In patients with subsyndromal anxiety or generalised anxiety disorder (GAD) an anxiolytic effect of Silexan was evident after 2 weeks. Patients treated with Silexan showed Hamilton Anxiety Scale (HAMA) total score decreases between 10.4 ± 7.1 and 12.0 ± 7.2 points at Week 6 and between 11.8 ± 7.7 and 16.0 ± 8.3 points at Week 10.

Conclusions: HAMA total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subsyndromal anxiety and comparable to lorazepam in its starting dose in patients with GAD. Silexan had beneficial effects on typical comorbidity symptoms of anxiety disorders, for example, disturbed sleep, somatic complaints, or decreased quality of life. Except for mild gastrointestinal symptoms, the drug was devoid of adverse effects and did not cause drug interactions or withdrawal symptoms at daily doses of 80 or 160 mg.

Similar articles

- [Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.](#)
Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S. Int Clin Psychopharmacol. 2010 Sep;25(5):277-87. doi: 10.1097/YIC.0b013e32833b3242. PMID: 20512042 Clinical Trial.

- [A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.](#) Woelk H, Schlafke S. Phytomedicine. 2010 Feb;17(2):94-9. doi: 10.1016/j.phymed.2009.10.006. Epub 2009 Dec 3. PMID: 19962288 Clinical Trial.
- [Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.](#) Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schlafke S. Wien Med Wochenschr. 2010 Dec; 160(21-22):547-56. doi: 10.1007/s10354-010-0845-7. PMID: 21170695 Review.
- [Silexan in anxiety disorders: Clinical data and pharmacological background.](#) Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Dienel A. World J Biol Psychiatry. 2018 Sep; 19(6):412-420. doi: 10.1080/15622975.2017.1331046. Epub 2017 Jun 19. PMID: 28511598 Review.
- [Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep--A randomized, placebo-controlled trial.](#) Kasper S, Anhelescu I, Dienel A. Eur Neuropsychopharmacol. 2015 Nov;25(11):1960-7. doi: 10.1016/j.euroneuro.2015.07.024. Epub 2015 Aug 7. PMID: 26293583 Clinical Trial.

[See all similar articles](#)

Cited by 6 PubMed Central articles

- [Efficacy and safety of lavender essential oil \(Silexan\) capsules among patients suffering from anxiety disorders: A network meta-analysis.](#) Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM. Sci Rep. 2019 Dec 2;9(1):18042. doi: 10.1038/s41598-019-54529-9. PMID: 31792285 Free PMC article.
- [Essential oil of lavender in anxiety disorders: Ready for prime time?](#) Malcolm BJ, Tallian K. Ment Health Clin. 2018 Mar 26;7(4):147-155. doi: 10.9740/mhc.2017.07.147. eCollection 2017 Jul. PMID: 29955514 Free PMC article.
- [Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.](#) Möller HJ, Volz HP, Dienel A, Schlafke S, Kasper S. Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):183-193. doi: 10.1007/s00406-017-0852-4. Epub 2017 Nov 17. PMID: 29150713 Free PMC article.
- [Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.](#) Lee G, Bae H. Biomed Res Int. 2017;2017:6596241. doi: 10.1155/2017/6596241. Epub 2017 Apr 19. PMID: 28503571 Free PMC article. Review.
- [The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice.](#) Möller HJ, Bandelow B, Volz HP, Barnikol UB, Seifritz E, Kasper S. Eur Arch Psychiatry Clin Neurosci. 2016 Dec;266(8):725-736. doi: 10.1007/s00406-016-0684-7.

Epub 2016 Mar 22. PMID: 27002521 Free PMC article. Review.

[See all "Cited by" articles](#)